Kaiwen Jiang
Psychiatric/Mental Health · Reno, NVNPI 1366035750
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 295 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 28.2% of the total. 2025 is the largest year on record at $1,956, 9.1 times the $215 reported in 2021. Among psychiatric/mental health clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 295 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$552
- E.r. Squibb & Sons, L.L.C.$380
- Indivior Inc.$374
- Vanda Pharmaceuticals Inc.$346
- plus $2K from 15 others
What the payments were for
- Food & beverage$6,29899%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 80 | $1,788 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 82 | $1,329 |
| Otsuka America Pharmaceutical, Inc. | 13 | $552 |
| E.r. Squibb & Sons, L.L.C. | 19 | $380 |
| Indivior Inc. | 19 | $374 |
| Vanda Pharmaceuticals Inc. | 20 | $346 |
| Alkermes, Inc. | 14 | $315 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $290 |
| Neurocrine Biosciences, Inc. | 11 | $236 |
| Lundbeck LLC | 7 | $148 |
| Johnson & Johnson | 4 | $146 |
| Axsome Therapeutics, Inc. | 5 | $119 |
| Idorsia Pharmaceuticals US Inc | 5 | $88 |
| Luye Pharma (USA) Ltd. | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Almatica Pharma LLC | 2 | $30 |
| Sage Therapeutics, LLC | 1 | $29 |
| Tris Pharma Inc | 1 | $19 |
| Myovant Sciences Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$461
- VRAYLAR$368
- ABILIFY ASIMTUFII$351
- COBENFY$119
- REXULTI$110
How this compares
$6,333 in reported general payments places this provider in the 90th percentile of 362 psychiatric/mental health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 50 | $170,940 |
| Abilify MaintenaAripiprazole | 59 | $169,202 |
| Invega TrinzaPaliperidone Palmitate | 13 | $117,358 |
| VraylarCariprazine Hcl | 52 | $74,586 |
| AristadaAripiprazole Lauroxil | 13 | $28,339 |
| CaplytaLumateperone Tosylate | 14 | $23,809 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $20,759 |
| Aripiprazole | 114 | $15,267 |
| Asenapine Maleate | 13 | $4,532 |
| Clozapine | 26 | $4,140 |
| Quetiapine Fumarate | 131 | $3,851 |
| Bupropion XlBupropion Hcl | 215 | $3,022 |
| Olanzapine | 60 | $2,226 |
| Haloperidol Decanoate | 42 | $2,078 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $2,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $146 | $288,29963 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $552 | $169,20259 claims |
| AbbVieVraylar | $1,788 | $74,58652 claims |
| Alkermes, Inc.Aristada | $315 | $28,33913 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,329 | $23,80914 claims |
| Axsome Therapeutics, Inc.Auvelity | $119 | $20,75918 claims |
| Almatica Pharma LLCSertraline Hcl | $30 | $755125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 362 psychiatric/mental health providers in Nevada.
Other psychiatric/mental health in Reno
- Okechukwu OlisaReno$7K
- Alana RogneReno$6K
- Doris AnukamReno$5K
- Megan SeivertReno$4K
- Denis WilliamsReno$4K
- Nathanael MellumReno$3K
- Jacqueline WilliamsReno$3K
- Michelle GiddingsLas Vegas$131K
- Patrick ApiladoLas Vegas$19K
- Joshua HamiltonLas Vegas$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.